Last week, we looked at three "champion stocks" that analysts at Bell Potter believe are great buy and hold options for investors. You can read about those ASX 200 shares here.
The good news is that there are a few more shares that the broker has on its list. Here are three other champion stocks to consider:
Brambles Limited (ASX: BXB)
The first ASX 200 champion stock to look at is Brambles. Bell Potter is a fan of this logistics solutions company, particularly given its defensive earnings and growth opportunities in emerging markets.
The broker explained:
A global logistics company operating in more than 60 countries, which provides reusable pallets, crates and containers for shared use by multiple participants throughout a supply chain under a model known as "pooling". The group primarily serves defensive growth sectors such as fast-moving consumer goods (dry food, grocery, and health and personal care), fresh produce and beverages. Further expansion into emerging markets should generate additional earnings growth.
Goodman Group (ASX: GMG)
This integrated industrial property company is a champion stock according to Bell Potter. The broker believes Goodman is well-placed for long term growth thanks to its world class portfolio and increasing demand for industrial property.
Bell Potter commented:
One of the world's largest integrated industrial property groups with operations centred around development, management and ownership throughout Australia, New Zealand, Asia, Europe, United Kingdom, North America, and Brazil. The long term outlook for industrial and logistics properties is favourable given the continuing growth in ecommerce (or on-line retail sales) and the growing middle class in developing countries.
Sonic Healthcare Limited (ASX: SHL)
A final ASX 200 champion stock for investors to consider is Sonic Healthcare. Bell Potter believes the pathology provider is well-placed for growth due to growing demand for pathology services and international expansion opportunities.
It explained:
The world's third largest pathology provider with significant operations in the USA, United Kingdom, Germany, Switzerland, Belgium, Australia and New Zealand. Against the backdrop of continuing growth in the demand for pathology services over the longer term, the group has further international expansion opportunities in both existing and new geographical markets.
